Shares of Canadian marijuana company Tilray fall sharply as it concludes a wild week that captivated investors.
There may be a technical reason for the magnitude of the rally in Canadian pot producer Tilray, which has captured the attention of traders everywhere: It's too expensive to bet against the stock.
The cannabis craze is hitting Wall Street, and some experts advise caution after marijuana companies undergo wild trading sessions.
Tilray shares have been on fire the previous two days, but with plenty of bumps along the way. That bumpy ride continued on Thursday.
Wall Street's obsession with marijuana stocks has propelled industry leaders to lofty market valuations. Canadian cannabis company Tilray is now larger than 45 percent of the stocks that comprise the S&P 500.
Five trading halts, a surge of 90% and all of its shares changing hands... all in a day's work for volatile pot stock Tilray.
The warning from the Food and Drug Administration on Wednesday cited recent data pointing to a sharp increase in underage use of the handheld nicotine devices, including Juul, Vuse and others. Since last year, FDA commissioner Scott Gottlieb and other federal officials have discussed e-cigarettes as a potential tool to ween adult smokers off cigarettes,...
Bristol-Myers Squibb said on Wednesday its experimental drug helped reduce the severity of the most common form of psoriasis in a mid-stage trial.
The vast majority of Amazon Prime members who have health insurance told Deutsche Bank that they would be willing to purchase prescription drugs on the online retailer's website.
Sept 10- A U.S. appeals court on Monday revived Swedish pharmaceutical company Orexo AB's lawsuit accusing a unit of Israel's Teva Pharmaceutical Industries Ltd of infringing a patent for its opioid addiction drug Zubsolv. Shares of Orexo closed 30.9 percent higher in Stockholm after the decision by the U.S. Federal Circuit Court of Appeals in Washington, D.C.,...
While most medical schools now offer some education about opioids, only about 15 of 180 American programs teach addiction including alcohol, tobacco and other drugs, The New York Times reports.
Merck's key cancer drug Keytruda has been approved for use in Europe in combination with chemotherapy in previously untreated lung cancer patients.
Sarepta Therapeutics CEO Douglas Ingram discusses the status of his company's drug trials and what's been driving the stock higher this year.
A marijuana ETF listed in Canada reached the $1 billion asset mark after liquor giant Constellation Brands announced a $4 billion investment in a marijuana company. That's considerable growth for an ETF that launched just a little over a year ago.
Synthetic marijuana is attractive to those who are looking for marijuana but either don't have access, the funds, or need to pass a clean urine test. But the risk of smoking spice outweigh the convenience cost according to a street drug researcher in The Conversation.
Dr. Marc Harrison, Intermountain Healthcare president and CEO, joins the 'Power Lunch' crew to discuss the Civica project, a team of seven firms making up about 500 hospitals partnering to form a non-profit generic drugmaker.
CNBC's Meg Tirrell reports on hospitals making their own generic medicines.
Can drug courts help solve America's opioid crisis? Judge-led therapy programs aim to help addicts kick the habit and get their lives back in ways that rehab alone can't, the Financial Times reports.
Don Blankenship had called Senate Majority Leader Mitch McConnell "Cocaine Mitch" during a failed bid to win the Republican nomination for Senate in West Virginia.
Bayer and Johnson & Johnson's campaign to widen the market for its heart drug Xarelto hit a snag on Sunday when a study for a potential new patient subgroup failed to show a statistically reliant benefit.